Protara Therapeutics Inc is trading 7.9% up at $4.25 in pre-market trading after investors reacted to news from the company's 2026 Annual Meeting.
- Shareholders approved an amendment to double the authorized common stock to 200 million shares, providing flexibility for future financings or strategic actions.
- The expansion of authorized shares is driving heightened investor interest and increased volatility in early trading sessions.